<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355991</url>
  </required_header>
  <id_info>
    <org_study_id>01327</org_study_id>
    <nct_id>NCT01355991</nct_id>
  </id_info>
  <brief_title>Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI</brief_title>
  <official_title>Acute and Chronic Effects of an Anticholinergic Agent or a Long-Acting Beta 2 Agonist on Levels of Exhaled Nitric Oxide and Pulmonary Function in Persons With Tetraplegia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James J. Peters Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kessler Institute for Rehabilitation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>James J. Peters Veterans Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the acute and chronic effects of a short course of treatment on spinal cord
      injured (SCI) individuals with either an anticholinergic agent (tiotropium) or with a β₂
      agonist (Salmeterol) on:

        -  Fraction of expired NO (FeNO)

        -  Selected Biomarkers of inflammation in exhaled breath condensates (EBC)

        -  Pulmonary function, as measured by pulmonary function tests and body plethysmography
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of an anticholinergic agent or beta 2 agonist on the fraction of expired NO (FeNO)</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>This will be a crossover trial. Baseline measurements will be taken, followed by two weeks of drug intervention (Salmeterol or Tiotropium Bromide). After two weeks the subject will return for post drug measurements. There will be a wash out period of four weeks, and then the subject will return again for the baseline measurements of drug 2, followed by two weeks of intervention and a final assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Selected Biomarkers of inflammation(TNF-alpha,Isoprostane 8, Leukotriene B4) in exhaled breath condensates (EBC)after intervention</measure>
    <time_frame>Approx. 8 weeks</time_frame>
    <description>The subject will be randomized to receive either anticholinergic agent or long acting Beta2 agonist. Measurements of EBC will take place at baseline, 1 hr post drug administration, and two weeks after intervention. Biomarkers of inflammation will be assessed by collected exhaled breath condensates, which will subsequently be sent for biochemical analysis. Markers include Isoprostane-8, TNF-Alpha, and Leukotriene B4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function, as measured by pulmonary function tests and body plethysmography</measure>
    <time_frame>Approx. 8 weeks</time_frame>
    <description>This will be a crossover trial. Baseline measurements will be taken, followed by two weeks of drug intervention (Salmeterol or Tiotropium Bromide). After two weeks the subject will return for post drug measurements. There will be a wash out period of four weeks, and then the subject will return again for the baseline measurements of drug 2, followed by two weeks of intervention and a final assessment. Pulmonary assessments include: Spirometry and Plethysmography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Anticholinergic Agent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Long Acting Beta 2 Agonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>18mcg/ capsule inhaled once daily for two weeks.</description>
    <arm_group_label>Anticholinergic Agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>50mcg inhalation twice daily for two weeks</description>
    <arm_group_label>Long Acting Beta 2 Agonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic Spinal Cord Injury (&gt;1 year post-injury)

          2. All American Spinal Injury Association (ASIA) classifications

          3. Stable tetraplegia (level of injury C3-C8, non-ventilator dependent)

          4. Age 18-65 years

        Exclusion Criteria:

          1. Smoking, active or history of smoking within last 6 months;

          2. Active respiratory disease;

          3. Known history of asthma during lifetime or recent (within 3 months) respiratory
             infections;

          4. Use of medications known to affect the respiratory system;

          5. Use of medications known to alter airway caliber;

          6. Coronary heart and/or artery disease;

          7. Hypertension;

          8. Adrenal insufficiency;

          9. Pregnancy;

         10. Severe Milk Protein Allergy;

         11. Lack of mental capacity to give informed consent;

         12. Previous allergic reaction or hypersensitivity to salmeterol or tiotropium;

         13. Individuals taking medication(s) with known /potential drug interactions or suggested
             therapy modification for concomitant use with salmeterol or tiotropium such as:

        (1) selective alpha-/beta- blockers: carvedilol, labetalol; (2) non-selective
        beta-blockers: Carteolol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Pindolol;
        Propranolol; Sotalol; Timolol); (3) CYP3A4 Inhibitors: (e.g, Atazanavir; Clarithromycin;
        Conivaptan; Darunavir; Delavirdine; Fosamprenavir; Imatinib; Indinavir; Isoniazid;
        Itraconazole; Ketoconazole; Lopinavir; Nefazodone; Nelfinavir; NiCARdipine; Posaconazole;
        QuiNIDine; Ritonavir; Saquinavir; Telithromycin; Voriconazole; (4) Iobenguane I 123 /
        Sympathomimetics: Albuterol; Aminophylline; Arformoterol; Armodafinil; Benzphetamine;
        Caffeine; Dexmethylphenidate; Dextroamphetamine; Diethylpropion; Dipivefrin; DOBUTamine;
        DOPamine; Doxapram; Dyphylline; EPHEDrine; EPINEPHrine; Fenoterol; Formoterol;
        Isometheptene; Levalbuterol; Levonordefrin; Lisdexamfetamine; Metaproterenol;
        Methamphetamine; Methylphenidate; Midodrine; Modafinil; Naphazoline; Norepinephrine;
        Oxymetazoline; Phendimetrazine; Phentermine; Phenylephrine; Pirbuterol; Propylhexedrine;
        Pseudoephedrine; Sibutramine; Terbutaline; Theophylline; Xylometazoline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miroslav Radulovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James J. Peters VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kessler Institute for Rehabilitation</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James J. Peters VA Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2011</study_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>James J. Peters Veterans Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>Miroslav Radulovic, M.D.</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Spinal Cord Injury</keyword>
  <keyword>Tetraplegia</keyword>
  <keyword>Pulmonary Function</keyword>
  <keyword>Bronchodilator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Cholinergic Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

